PMD vs. CNTG, BGLC, DMTK, OPGN, XGN, ENZ, TTOO, AYTU, ETAO, and KPRX
Should you be buying Psychemedics stock or one of its competitors? The main competitors of Psychemedics include Centogene (CNTG), BioNexus Gene Lab (BGLC), DermTech (DMTK), OpGen (OPGN), Exagen (XGN), Enzo Biochem (ENZ), T2 Biosystems (TTOO), Aytu BioPharma (AYTU), ETAO International (ETAO), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "medical" sector.
Psychemedics (NASDAQ:PMD) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends, community ranking and profitability.
Psychemedics has higher earnings, but lower revenue than Centogene.
Psychemedics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Centogene has a beta of -0.81, meaning that its share price is 181% less volatile than the S&P 500.
Centogene has a net margin of 0.00% compared to Psychemedics' net margin of -18.39%. Centogene's return on equity of 0.00% beat Psychemedics' return on equity.
Centogene has a consensus target price of $1.50, suggesting a potential upside of 206.81%. Given Centogene's higher possible upside, analysts clearly believe Centogene is more favorable than Psychemedics.
In the previous week, Psychemedics and Psychemedics both had 1 articles in the media. Centogene's average media sentiment score of 1.00 beat Psychemedics' score of 0.00 indicating that Centogene is being referred to more favorably in the news media.
32.1% of Psychemedics shares are held by institutional investors. Comparatively, 9.9% of Centogene shares are held by institutional investors. 24.0% of Psychemedics shares are held by company insiders. Comparatively, 1.9% of Centogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Psychemedics received 102 more outperform votes than Centogene when rated by MarketBeat users. Likewise, 74.35% of users gave Psychemedics an outperform vote while only 64.52% of users gave Centogene an outperform vote.
Summary
Psychemedics and Centogene tied by winning 6 of the 12 factors compared between the two stocks.
Get Psychemedics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Psychemedics Competitors List
Related Companies and Tools
